A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

Active:	Yes
Cancer Type:	Unknown Primary	NCT ID:	NCT05263999
Trial Phases:	Phase III	Protocol IDs:	EQ-100-02 (primary) NCI-2022-02430
Eligibility:	12 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Equillium
NCI Full Details:	http://clinicaltrials.gov/show/NCT05263999

Summary

This is a multi-center study to compare the efficacy and safety of itolizumab versus
placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI
involvement, in combination with corticosteroids

Objectives

This study will enroll 200 subjects at approximately 125 sites globally. Subjects will be
randomized in a 1:1 ratio to active or placebo and will receive a total of 7 doses
administered intravenously approximately every 2 weeks. The study follows the patients
for a total of approximately 365 days.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.